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Abstract 
 
Lymphoma is the third most common neoplasia in the world. Within lymphomas, non-Hodgkin 
lymphoma (NHL) is the most common affecting mainly B cells. 
For more than three decades, chemotherapy and radiotherapy have been the only treatments available, 
but since the discovery of Rituximab, a new era of lymphoma therapy was inaugurated, once it was the 
first monoclonal antibody approved against the CD20 receptor. 
The CD20 receptor is an antigen expressed on the B-cells surface, and it is present nearly in all of its 
maturational development, being absent only in the stages of the pro-B lymphocyte and plasma cells. 
Furthermore, the CD20 receptor is also present on >90% of the B-cell NHL. These characteristics make this 
receptor an ideal target for immunotherapy.  
Besides the success of Rituximab, various mechanisms of resistance have been developed by the tumoral 
cells against this antibody, such as the decrease of the CD20 expression on B-cells, immunogenicity, 
structural changes affecting the binding region of the CD20 antibody or alterations in the cell membrane. 
New anti-CD20 antibodies have been developed to overcome the disadvantages of Rituximab, such as 
Ofatumumab and Obinutuzumab, presenting a different immunogenicity and binding to the different 
epitopes on the target with a different affinity. Apart from the progress in the lymphoma therapy, a 
significant population of patients still succumbs to this disease, as tumoral cells are always changing, 
making the search for better antibodies a never-ending process. Thus, the aim of this project consisted in 
the development and characterization of a new antibody against the CD20 receptor. To achieve this goal, 
the potential of rabbit derived single-domain antibodies (sdAbs) as therapeutic molecules were explored. 
For that, one rabbit was immunized with the CD20 receptor and an immune VH and VL sdAb library was 
generated. Then, a subtractive cell phage display screening was used for antibody selection. This approach 
allowed a specific selection of one sdAb in the VL format against the CD20 receptor in cells. In summary, 
the strategy explored in the present project resulted in an antibody that, according to its characteristics, 
could be a promising candidate in the treatment of NHL and other B-cell malignancies. 
 
Keywords: 
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Resumo alargado  
 
Os linfomas são a terceira neoplasia mais comum no mundo, sendo os linfomas não-Hodgkin os mais 
frequentes. Dentro dos linfomas não-Hodgkin, cerca de 85-90% são de células B. Os linfomas 
desenvolvem-se maioritariamente a partir dos nódulos linfáticos, no entanto podem formar-se a partir de 
qualquer outro tecido. 
Durante mais de três décadas, os únicos tratamentos disponíveis para esta doença eram a quimioterapia 
e a radioterapia. No entanto, com a descoberta do Rituximab, um anticorpo específico para o recetor CD20 
presente nos linfomas de células B, começou uma nova era no campo das imunoterapias.  
O anticorpo Rituximab, uma vez que foi o primeiro a ser descoberto, faz parte da primeira geração de 
anticorpos anti-CD20. Este é um anticorpo quimérico, uma vez que é constituído por um IgG1 glicosilado 
composto por uma região constante kappa humana e regiões variáveis leves e pesadas murinas. Este 
anticorpo atua essencialmente através de três principais mecanismos de ação: citotoxicidade mediada por 
anticorpos (ADCC); citotoxicidade dependente do complemento (CDC) e indução da apoptose. 
O recetor CD20 é uma molécula expressa na superfície das células B e está presente na maioria das fases 
de maturação destas células, com exceção da fase de linfócitos pró-B e nas células plasmáticas. Para além 
disso, está presente em mais de 90% dos linfomas não-Hodgkin de células B. No entanto, apesar da sua 
função ainda não ser totalmente conhecida, pensa-se que possa estar envolvido no fluxo de cálcio. Este 
recetor é uma fosfoproteína não glicosilada com 4 domínios membranares: os domínios N e C terminal 
que são intracitoplasmáticos e 2 loops adicionais que são extracelulares. Devido a estas suas 
características, o recetor CD20 é considerado um bom alvo para imunoterapias, nomeadamente terapias 
para linfomas não-Hodgkin de células B. 
Apesar do sucesso do Rituximab, têm vindo a ser descritos vários mecanismos de resistência das células 
tumorais contra este anticorpo, nomeadamente a diminuição da expressão de CD20, mudanças estruturais 
que afetam o local de ligação do anticorpo à molécula ou alterações na membrana da célula, o que 
diminuiu a sua eficácia. Este aspeto fez com que fosse necessária a contínua procura por novos anticorpos 
para colmatar as lacunas do Rituximab. Assim, ao longo dos anos, foram descobertos novos anticorpos 
específicos para CD20, como o Ofatumumab e o Obinutuzumab, que têm uma diferente imunogenicidade 
e reconhecem diferentes epítopos na molécula CD20 aos quais se ligam com diferentes afinidades, 
atuando assim com diferentes mecanismos de ação. Ainda assim, este tipo de doença continua a afetar 
imensas pessoas, muitas vezes não existindo um tratamento eficaz devido às múltiplas resistências das 
células tumorais. Tendo em conta este contexto e uma vez que os anticorpos disponíveis no mercado não 
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conseguem resolver estes problemas, a procura por novos anticorpos mais vantajosos continua. 
Atendendo a esta necessidade, o objetivo deste projeto é o desenvolvimento e caracterização de um 
anticorpo de pequeno domínio específico para CD20. Os anticorpos de pequenos domínios têm várias 
vantagens em relação aos IgGs completos, principalmente devido ao seu reduzido tamanho, que faz com 
que estes anticorpos tenham melhor acesso ao alvo na superfície da célula, para além disso podem ainda 
ser facilmente expressos em bactérias como proteína. Têm ainda a vantagem, como moléculas 
terapêuticas, de serem mais estáveis em circulação que os anticorpos completos. Estas características 
permitem uma administração de maiores quantidades por grama de produto, o que leva a um aumento 
significativo da potência por dose e na redução do custo de produção. 
Para o desenvolvimento do projeto, inicialmente foi imunizado um coelho com o péptido CD20 e com 
células HEK 293T transfetadas com o recetor CD20. Antes de cada imunização, o soro era recolhido para 
ser avaliado através de ELISA. Ao dia 89, quando foi atingido um elevado título de anticorpos, procedeu-
se à recolha do soro final e à eutanásia do coelho. Os ensaios de ELISA permitiram confirmar que o soro 
extraído após as imunizações estava a reconhecer não só as células Raji, que contêm à sua superfície CD20, 
mas também o péptido CD20, por outro lado o soro recolhido antes das imunizações não reconhecia nem 
as células Raji, nem o péptido. Após a eutanásia, foram recolhidos o baço e a medula que são os órgãos 
onde se encontra um maior número de células plasmáticas que produzem anticorpos. A partir destes 
órgãos, procedeu-se à extração de ARN usando o reagente Tri. A partir do ARN extraído foi possível 
sintetizar a primeira cadeia de ADN. O cADN sintetizado foi utilizado para a construção de bibliotecas 
imunes de pequenos domínios de anticorpos específicos para o recetor CD20, através da amplificação por 
PCR das famílias de cadeias variáveis leves e pesadas. Esses produtos resultantes da amplificação foram 
clonados no vetor pComb3x, que é necessário na técnica de phage display, resultando numa biblioteca 
imune com uma grande diversidade, ideal para este tipo de seleção. Em seguida, as bibliotecas resultantes 
foram selecionadas através da tecnologia de phage display que permite a seleção de anticorpos específicos 
para CD20 em células que contenham esse recetor. Esta tecnologia baseia-se na engenharia genética de 
bacteriófagos e em várias rondas de seleção contra o antigénio e propagação dos fagos. Resumidamente, 
os fagos vão conter à sua superfície o fenótipo correspondente ao genótipo encapsulado no seu interior 
que contem a sequência correspondente aos fragmentos de ADN obtidos através da construção das 
bibliotecas de anticorpos. Seguem-se várias rondas de seleção onde vão sendo eliminados os anticorpos-
fagos que não se ligam ou que possuem uma fraca ligação às células que contêm o antigénio, neste caso 
o recetor CD20, através de várias lavagens. Estas rondas vão sendo repetidas até obtermos uma população 
de anticorpos específica para o alvo. Para este phage display, foram utilizados 3 tipos de células: células 
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Raji, que está descrito que expressam o CD20, pois são células de linfoma B; células HEK 293T que não 
expressam CD20 e por isso foram utilizadas para eliminar os anticorpos não específicos para este recetor; 
células Jurkat, que tal como as anteriores não possuem CD20, pois tratam-se de células T de leucemia 
aguda e que por isso foram também utilizadas para eliminar anticorpos não específicos. Esta seleção 
resultou num conjunto de anticorpos-fagos específicos para o recetor CD20, resultado que foi confirmado 
através de Western Blot. Após a seleção por phage display, foi necessário fazer uma seleção em larga 
escala para avaliar os anticorpos que melhor eram expressos e que melhor se ligavam ao alvo. Para esta 
avaliação da expressão foi necessário clonar o ADN resultante dos fagos selecionados por phage display, 
num outro vetor que permitisse a expressão de proteína, neste caso o vetor pT7-PL. Esta avaliação da 
ligação e expressão foi feita através de ensaios de ELISA com extrato proteico de células Raji e células Raji. 
Para além disso, após várias seleções os melhores 10 clones foram sequenciados para avaliar a homologia 
entre si e verificar os CDRs. Através do alinhamento da sequência de aminoácidos obtida a partir da 
sequenciação, verificou-se que 9 dos clones eram iguais, restando assim apenas 2 clones. A especificidade 
dos dois clones selecionados para o recetor CD20 foi avaliada através de Western Blot, sendo que um deles 
(anticorpo no formato VL) era específico para o recetor pretendido.  
Estas metodologias levaram à seleção de um anticorpo de pequeno domínio específico para CD20, que 
devido às suas características únicas e diferentes dos que já existem no mercado poderá ser um promissor 
candidato para ser usado como agente terapêutico para linfomas de células B que expressem o recetor 
CD20. 
 
 
Palavras- Chave: 
CD20; Linfoma; Imunoterapia; Anticorpos de pequeno domínio; Phage Display  
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1. Introduction  
1.1. Cancer and Lymphoma 
 
Cancer is the second most common cause of death in the United States, making this disease the major 
public health problem in the world, killing one in every four persons, remaining one of the most challenging 
diseases to treat.  
Lymphoma, which is one kind of hematological cancer, is the third most common neoplasia in the world 
and is predominantly a cancer of B-lymphocytes.1,2 Within lymphomas, non-Hodgkin lymphoma (NHL) is 
the most common hematologic malignancy and accounts for approximately 4% of all adult cancers in the 
United States.1 NHL comprises a heterogeneous group of cancers: 85-90% from B lymphocytes and the 
remainder derives from T lymphocytes or NK cells. These malignancies usually develop in the lymph nodes, 
but can occur in almost any tissue.3  
 
 
1.1.1. Current and emerging therapies for Cancer and  Lymphoma  
 
For more than three decades, the only therapies available for lymphoma and other kinds of cancer were 
chemotherapy and radiotherapy.4 However, with the advances in the field of immunology, recombinant 
DNA technology and protein engineering, new therapies for cancer emerged over the past years. These 
therapies, known as immunotherapies, use part of the immune system to fight diseases, stimulating it to 
specifically attack cancer cells, or even using immune system proteins.  
There are various types of immunotherapies, but monoclonal antibodies (mAbs) are one of the most 
important and successful strategies for treating patients.5 Currently, about fifty monoclonal antibodies 
have been approved in the United States and Europe for treatment of a variety of diseases including 
cancer.6,7 
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 Antibody therapy can function through mediating alterations in antigen or receptor function, 
modulating the immune system or delivering a specifying drug that is conjugated to an antibody that 
targets a specific antigen. Mechanisms of cell killing by antibodies can be summarized in direct action of 
the antibody; immune-mediated cell killing mechanisms and specific effects of an antibody on tumor 
vasculature and stroma. These mechanisms are outlined in Fig. 1.5 
 
 
 
1.1.2. CD20 as therapeutic target  
 
The MS4A1 gene located on chromosome 11q12.2 encodes the human CD20. This receptor is a non-
glycosylated phosphoprotein with four membranes spanning domains, the N - and C – terminal domains, 
which are intracytoplasmic and two additional extracellular loops (Supplementary figure 1). Its functions 
are not fully understood, however, it is thought that they may be involved in the calcium flux.8  
The CD20 receptor is expressed on the B-cells surface and is present during nearly all its maturational 
development, only being absent in the pro-B lymphocyte and plasma cells. Furthermore, CD20 is also 
Figure 1 - Mechanisms of cell killing by antibodies. a) Direct tumor cell killing can be mediated by receptor agonist activity or 
antagonist activity leading both to apoptosis. It can also be mediated by a conjugated antibody used to deliver a payload to a 
tumor cell. b) immune-mediated tumor cell killing include mechanisms such as induction of phagocytosis, complement activation 
(CDC); antibody-dependent cellular cytotoxicity (ADCC); genetic modified T cells targeted to the tumor by single-chain variable 
fragments (scFv); T cells being activated by antibody-mediated cross-presentation of antigen to dendritic cells; and inhibition of 
T cell inhibitory receptor. c) vascular and stromal ablation can be induced by stromal cell inhibition; delivery of a toxin to stromal 
cells; and delivery of a toxin to the vasculature. Adapted from Scott et al, 2012.5 
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present on >90% of the B-cell NHL.8,9 Therefore, these characteristics make this receptor an ideal target 
for immunotherapy.  
The central challenge of immunotherapies has been the identification of suitable targets. Due to its 
characteristics, the CD20 receptor is one of the most promising targets for this approach.  
For lymphoma treatment, Rituximab was the first monoclonal antibody against the CD20 receptor 
approved by the FDA, in 1997.10  Since its approval, chemotherapy in combination with immunotherapy 
remains the standard treatment.11  
Throughout the years, the discovery of new antibodies for the CD20 receptor contributed to the 
development of new therapeutics and the quality of life of patients. Nevertheless, tumoral cells are always 
changing, making the search for better antibodies a never-ending process. 
 
 
1.2. Antibodies  
1.2.1. Characteristics and proprieties of antibodies  
 
Antibodies, also named immunoglobulins, are a family of glycoproteins produced in response to 
exposure to foreign structures, known as antigens. Nonetheless, antibodies display remarkable variability 
in the regions that bind antigens, possess a common structure of four polypeptide chains, consisting of 
two identical light chains and two identical heavy chains, which confer to each antibody at least two 
antigen-binding sites. Heavy and light chains are made of amino-terminal variable regions and carboxyl-
terminal constant regions. In light chains, the variable and constant regions are composed of one VL and 
CL domain, while heavy chains are made of one variable domain (VH) and three constant domains (CH1, 
CH2 and CH3). The variable domains of light and heavy chains contain three hypervariable regions that are 
also known as complementary-determining regions (CDRs), as they can interact with the bound antigen. 
These regions differ in length and sequence among antibodies, which is why they are responsible for the 
specificity and affinity of the antibodies to the antigen. Light chains are bound to the heavy chains by a 
disulfide bond formed between cysteine residues and multiple non-covalent interactions. Heavy chains 
are also covalently bound by disulfide bonds. Between the CH1 and CH2 domains is located the hinge 
region, which is a flexible segment of the heavy chain that allows the two antigen-binding sites to operate 
independently. The antibody molecule forms a Y shape, meaning that the two identical heavy and light 
chains contribute to each arm of Y, while its base is composed by C-terminal domains of the heavy chain. 
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The two-paired heavy and light chains are named Fab (antigen-binding fragments), responsible for the 
antigen binding, while the C-terminal domains are known as constant fragment (Fc), responsible for the 
recruitment of the effector functions of the immune system.  
 In humans, it is possible to recognize five classes of immunoglobulins, namely IgG, IgA, IgM, IgD and IgE, 
which can differ in size, charge, amino acid sequence and carbohydrate content.  IgG is the most 
predominant immunoglobulin present in normal human serum and the most used format of therapeutic 
antibodies (Fig. 2). Rituximab against the CD20 receptor is an example of this format of therapeutic 
antibodies.12–14 
 
 
1.2.2. Rituximab, the first chimeric IgG anti-CD20 
 
Rituximab is a chimeric murine/human antibody consisting of a glycosylated IgG1 with a human kappa 
constant regions and murine light and heavy chain variable regions. This antibody is included in the first 
generation of anti-CD20 antibodies and has three main mechanisms of action: antibody-dependent cell-
mediated cytotoxicity (ADCC); complement-dependent cytotoxicity (CDC) and induction of apoptosis.11,15  
Despite the success of rituximab, various mechanisms of resistance have been developed by the tumoral 
cells against this antibody, such as the decreasing of CD20 expression on B-cells, structural changes 
affecting the binding region of the CD20 antibody or alterations in the cell membrane.11 Thus, new anti-
CD20 antibodies have been developed, such as Ofatumumab and Obinutuzumab, which show different 
immunogenicity, binding to different epitopes on the target with a different affinity (Fig. 3).16 
These new antibodies discovered for the CD20 receptor can overcome some disadvantages of Rituximab; 
however they have also a conventional format of IgG and have shown some mechanisms of resistance and 
immunogenicity.17 Within this context, there is still an urgent need to identify and develop new antibody 
Figure 2 - IgG structure. IgG is composed by two heavy and two light chains. Constant regions constitute the Fc domain and 
variable regions constitute the Fab domain, allowing antigen binding. Adapted  from Weiner et al, 2010.34   
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molecules and scaffolds for NHL treatment. A promising alternative to conventional mAbs molecules are 
recombinant antibody fragments.  
 
 
 
1.2.3. Novel therapeutic antibodies  
 
As mentioned above, most marketed antibodies are composed of a full-length IgG molecule that 
provides for a long half-life and effector functions. However, there is a range of therapeutic applications 
in which other antibody formats may be more desirable. For instance, in some conditions, a long serum 
half-life may increase the antibody immunogenicity, and inappropriate activation of Fc-receptor-
expressing cells may lead to massive cytokine release and associated toxic effects. In addition, due to their 
high molecular weight (~150 kDa), IgG antibodies are known to diffuse poorly into tumors and clear slowly 
from the body. Therefore, to avoid Fc-associated effects in some clinical settings and address the size 
limitations of IgGs, smaller antibody molecules such as the antigen-binding fragment (Fab), the variable 
fragment (Fv) and VL or VH single domain antibodies (sdAbs) may be constructed and have become more 
attractive as therapeutic agents (Fig. 4).18,19  
 
 
 
 
 Figure 3 - Structure of CD20 and epitopes recognized by Rituximab, Ofatumumab and Obinutuzumab (GA101). Adapted from 
Klein et al, 2013.15 
 
  
6 
 
1.2.3.1. Single-domain antibodies 
 
Single domain antibodies (sdAbs) are the variable domain of heavy (VH) or light (VL) chains. These 
fragments are the smallest functional antigen-binding fragments (11kDa to 15kDa)  that can be isolated 
from conventional IgGs.20 sdAbs show several advantages mainly related with their reduced size. One of 
them is the easy access to the epitopes on the target surface, which cannot be reached by IgG or larger 
antibody fragments (ex: Fab or scFv). Furthermore, sdAbs can be expressed efficiently in bacteria as active, 
soluble and robust proteins.  Their reduced size is also an advantage because sdAbs can penetrate solid 
tissues and tumors more efficiently.7 Moreover, since sdAbs lack the Fc domain, the non-specific uptake 
in tissues that highly express Fc receptors is low as well their immunogenicity’s. As therapeutic molecules, 
sdAbs are more stable than full-sized antibodies in circulation, meaning that they could be taken orally or 
delivered via the pulmonary route. These features allow the administration of higher molar quantities per 
gram of product, which should provide a significant increase in potency per dose and a reduction in overall 
manufacturing cost.21 In addition, sdAbs can be efficiently selected by in vitro screening approaches, such 
as the Phage Display technology. Taking in consideration all these advantages, sdAbs have become a 
promising alternative to conventional antibodies for challenging clinical applications such cancer and NHL.  
 
 
 
1.3. Selection of monoclonal antibodies  
 
Mouse hybridoma technology, described in 1975 by Kohler and Milstein, enabled the production of 
monoclonal antibodies through the fusion of myeloma cells with antibody producing B-cells.22 However, 
Figure 4 - Structure of antibody domains. a) Antigen- binding fragments (Fabs). b) Single-chain variable fragments (scFv). c) Heavy 
and light chains (VH and VL domains). Adapted  from Aires da Silva et al, 2008.35  
a) 
b) 
c) 
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because hybridoma antibodies are typically originate from murine sources, this limits their therapeutic 
applications due to human anti-mouse antibody reaction.23 To overcome this limitation, several  strategies  
have been developed, such as chimerization and humanization.24 In addition, new methods that use in 
vitro display technology have been introduced, such as antibody phage display and yeast, ribosome and 
bacterial systems. The phage display has been the most established and is currently the best antibody 
selection method use in the development of therapeutic antibodies.25 
 
 
1.3.1. Phage display technology  
 
Phage display was initially described by Smith in 198526 and is based on genetic engineering of 
bacteriophages (viruses that infect bacteria) and repeated rounds of antigen-guided selection and phage 
propagation.27 In this technique, antibody genes are linked to the amino terminus region of the phage 
minor coat protein pIII. When expressed, the encoded fusion product is incorporated into the mature 
phage particle during normal biogenesis. The resulting phage particle expresses antibodies on its surface 
and contains the antibody encoding gene. The linkage of displayed antibody phenotype with encapsulated 
genotype via the phage surface, consists in the crucial advantage of this technology.28 
The most common screening method is based on enriching the phages clones with binding affinity for 
the target by a process called panning. Each panning consists of multiple rounds of phage binding to the 
antigen, washing, elution and reamplification of the phage binders. During each round, specific binders 
are selected out from the pool by washing away non-binders and selectively eluting binding phage clones. 
Usually, three to six rounds of binding, elution and amplification (panning) are sufficient to generate 
antibodies with high affinity and specificity (Fig. 5).27 
 Various types of phage display libraries may be used: 1) immune libraries that have been constructed 
from variable domains of antibody genes of B cells derived from different kinds of immunized animals such 
as rabbits and mice; 2) naïve libraries, derived from non-immunized donors of B cells, which have been 
constructed from a pool of V-genes of IgM mRNA;29 3) synthetic libraries that also derived from non-
immune sources as their ranges were prepared synthetically by combining germ line gene sequences 
together with randomized complementary determining regions (CDRs) that are responsible for antigen 
binding.30 Due to its characteristics, phage display presents itself as a technology with enormous potential 
for the selection of promising  antibodies.  
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1.4. Objectives  
 
Due to the disadvantages that antibodies, currently in the market for the CD20 receptor in B-cell 
malignancies possess, such as size, immunogenicity, as well as the resurgence of several resistances, the 
development of more promising antibodies for this target is an urgent need.  Taking this into account, the 
aim of this project was the development and characterization of a new antibody against CD20 that could 
be efficiently used in the future in the treatment of NHL and other B-cell malignancies. To achieve this 
goal, the potential of rabbit derived sdAbs for therapeutic applications was explored and a subtractive cell 
phage display screening was used as a functional selection. Briefly, the project consisted in following 
tasks/aims:  
1) Rabbit immunization with CD20; 
2) Construction of immune sdAb libraries against the CD20; 
3) Selection of sdAbs by phage display technology;  
4) Screening and characterization of selected sdAbs against CD20.  
The present work was realized in Faculty of Veterinary Medicine of University of Lisbon, Faculty of Sciences 
of University of Lisbon and Technophage SA, headquartered in Instituto de Medicina Molecular (IMM), 
Faculty of Medicine of University of Lisbon.  
Figure 5 – Schematic representation of a round of selection (panning) for phage display. Adapted from Ruigrok et al, 2011.36 
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2. Material and Methods 
2.1. Cell culture 
 
Cell lines used in this work were cultured with RPMI 1640 (Lonza) or DMEM (Lonza) supplemented with 
10% fetal bovine serum, penicillin and streptomycin. Cells were maintained in a humidified incubator at 
37°C and 5% CO2.  
Cells were lysed with Ripa buffer (25mM TrisHCL pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS) (Thermo Scientific) to obtain the total cell extract. Total protein was quantified 
using the NanoDrop™ 2000c Spectrophotometer (Thermo Scientific).  
 
 
2.2. Transfection of human CD20 into HEK 293T cells 
 
The HEK 293T cells (ATCC) were transfected using the FuGENE® HD (Roche), according to the 
manufacturer’s instructions. For that purpose, 8 µl of FuGENE® HD was added to the 80 µl of medium and 
3 µg of pFUGW vector CD20, to a final volume of 100 µl. Then, the mixture was added to each well 
containing the cells plated. The plate was swirled and the cells incubated for 4 hours. After incubation, the 
medium was changed and the cells incubated for 48 hours. After 48 hours, cells were washed and 
resuspended in PBS 1x and injected in the rabbit.  
 
 
2.3. Rabbit immunizations  
 
A New Zealand White rabbit was immunized with the CD20 peptide (141-184 aa) and HEK 293T cells 
transfected with CD20 vector through subcutaneous injections. The injections were administrated in 2 - 3 
weeks for 3 months. 
To evaluate the serum specificity and titer, serum collected before and after bleeding from the rabbits 
was analyzed by ELISA using either Raji cells (ATCC) or the CD20 peptide as antigen, and Peroxidase-
conjugated goat anti-rabbit antibody (Jackson Immune Research) as secondary antibody.  
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Serum was purified using an AKTAtm start system in order to evaluate serum activity and titer against the 
CD20 receptor. For protein purification, 1 ml HiTrap™ Protein A HP was used. The column was equilibrated 
with PBS 1x, pH 7.4. Bound proteins were eluted from the column with 0.1 M citric acid. To the collecting 
tubes, 200 µl of 1M tris-HCl, pH 9.0, were added to neutralize samples.  
 
 
2.4. sdAbs immune library construction  
2.4.1. Isolation of Total RNA 
 
Five days after the final boost, spleen (SP) and bone marrow (BM) were harvested, homogenized and 
incubated in 10 ml of Tri reagent at room temperature for 5 minutes. Then, 20 ml of Tri reagent was added 
to each sample, and then centrifuged at 2500 g for 10 minutes at 4°C. The pellets were discarded, and for 
each supernatant, 3 ml of 1-Bromo-3-chloropropane BCP was added. Samples were agitated and 
incubated for 15 minutes at RT. Next, they were centrifuged at 17500 g for 15 minutes at 4°C. The colorless 
aqueous phase of each sample was transferred to a new centrifuge tube containing 15 ml of isopropanol. 
Samples were agitated and incubated for 10 minutes at RT. The samples were then centrifuged at 17500 
g for 10 minutes at 4°C. The supernatant was discarded and 30 ml of 75% ethanol was added to the pellet. 
Centrifugation at 17500 g for 10 minutes, at 4°C, was then performed. Supernatants were then discarded, 
and pellets air-dried at RT. Finally, each pellet was resuspended in 500 µl of RNase-free water. The RNA 
concentration and purity was evaluated by measuring the samples absorbance at 260 nm in a NanoDrop™ 
2000c Spectrophotometer (Thermo Scientific) and on an agarose gel electrophoresis, respectively.   
 
 
2.4.2. First strand cDNA synthesis 
 
Complementary DNA (cDNA) was synthetized by reverse transcription from total RNA using the 
Transcriptor High Fidelity cDNA Synthesis Kit (Roche), according to the manufacturer’s instructions.  After 
synthesis, cDNA was quantified using the NanoDrop™ 2000c Spectrophotometer (Thermo Scientific) 
through the measurement of the samples absorbance. The integrity of the synthetized cDNA was 
evaluated on a 1% agarose gel in TAE 1% by ethidium bromide staining under UV light with Chemidoc™ 
XRS+ (Bio-Rad). 
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2.4.3. PCR amplification of single domains antibody genes  
 
PCR was performed to amplify the heavy-chain variable (VH) and light-chain variable regions (VL) from 
the rabbit’s cDNA. The following conditions were used: an initial denaturation step, at 98°C for 30 seconds; 
a denaturation for 10 seconds at 98 °C; an annealing for 30 seconds at 56 °C and an extension for 60 
seconds at 72°C, for 30 cycles; final extension for 10 minutes at 72°C. For the amplification of the rabbit’s 
VH coding sequences, a four primer combination was used and for the VL, a ten primer combination 
(shown in the supplementary data section and Fig. 6). For each reaction, 500 ng of cDNA was used in a mix 
with 0.5 µM of Primer Forward and Reverse (20 pmol/µl), buffer 1x (5X), 3 mM of MgCl2 (50 mM), 200 µM 
of dNTPs (10 mM), 0.02 U/µl of Phusion High Fidelity DNA polymerase (Thermo Scientific) and miliQ water 
to a final volume of 50 µl. 
Each reaction was evaluated on a 2% agarose gel by ethidium bromide staining under UV light with 
Chemidoc™ XRS+ (Bio-Rad). 
 
 
2.4.4. Precipitation of PCR products 
 
To concentrate the PCR products, DNA precipitation with Sodium Acetate was performed. A mixture 
with 1/10 of the volume of 3 M NaOAc, 2.5 volumes of cold absolute EtOH and 1 µl of glycogen (Roche) 
was added to the DNA, and then incubated overnight at -80°C. After incubation, the mixture was 
centrifuged at 13200 rpm for 1 hour at 4°C, the supernatant was discarded, 1 ml of cold 70% EtOH was 
added to the pellet for washing and then centrifuged one more time. The supernatant was removed and 
the pellet was dried and resuspended in miliQ water (the amount was adjusted to each library). 
 
 
Figure 6 – Generation of VH and VL antibody fragments by PCR. 
  
12 
 
2.4.5. Purification of PCR products 
 
In order to purify DNA, PCR products were separated by electrophoresis on a 2% low-melt agarose gel 
in TAE 1x buffer. DNA with the expected size was extracted from the gel with a blade scapel and purified 
with the QIAquick® Gel Extraction Kit (Qiagen), according to the manufacturer’s instructions. Then, DNA 
was precipitated as described above. 
DNA concentration was determined using NanoDrop™ 2000c Spectrophotometer (Thermo Scientific) 
through the measurement of the samples absorbance. 
   
 
2.4.6. Digestion of vector DNA and PCR products with restriction enzyme SfiI 
 
For the PCR products digestion, 10 µg of purified DNA, 160 units of Restriction Endonuclease Sfi I (40 
U/µl) (Roche), 20 µl of buffer M (10x) and miliQ water were used to obtain a final volume of 100 µl. For 
the pComb3x vector digestion, 10 µg of vector, 120 units of Sfi I, 20 µl of buffer M (10x) and miliQ water 
were used to obtain a final volume of 100 µl. Both digestions were incubated overnight at 50°C. 
After digestion, vector and PCR products were purified on a 0.8% and 2% low melt agarose gel, 
respectively. DNA with the expected size was then removed from the gel and extracted by QIAquick® Gel 
Extraction Kit (Qiagen), and precipitation once again performed. Later, digested products were quantified 
using the NanoDrop™ 2000c Spectrophotometer (Thermo Scientific). 
 
 
2.5. Phage display library 
2.5.1. Cloning of PCR products into pComb3x vector  
 
In order to clone VL and VH PCR libraries into pComb3x, a ligation was performed using 1.4 µg of vector, 
4.2 µg of insert, 20 µl of ligase buffer (10x), 5 µl of T4 DNA ligase (BioLabs) and miliQ water to obtain a final 
volume of 200 µl. The ligation was incubated overnight at 16°C. The following day, DNA precipitation with 
sodium acetate was performed, following the steps described above, and DNA pellet was resuspended in 
20 µl of miliQ water.  
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Each 5 µl of ligation was inserted into 60 µl of electrocompetent E.coli ER2738 (Lucigen®) by 
electroporation. For this, an electrical shock at 1.8 kV, 25 µF and 200  was performed. After, 1 ml of SOC 
medium was added to each cuvette and the final volume was adjusted to 5 ml. The reaction was incubated 
for 1 hour at 37°C, agitated at 200 rpm. After 1 hour, 4.5 µl of ampicillin (100 mg/ml) was added and 
incubated at 37°C, agitated at 200 rpm. Next, 10 ml of pre-warmed SB medium with 3 µl of ampicillin (100 
mg/ml) and 15 µl of tetracycline (5 mg/ml) were added to the culture and incubated for 1 hour at 37°C, 
agitated at 200 rpm. After incubating for 1 hour, 2 ml of helper phage VCSM13 and 183 ml of pre-warmed 
SB medium with 92.5 µl of ampicillin (100 mg/ml) and 185 µl of tetracycline (5 mg/ml) were added to the 
culture. The culture was agitated at 200 rpm for 1.5 hours at 37°C. Finally, 280 µl of kanamycin was added 
and incubated overnight at 37°C, agitated at 200 rpm. 
The following day, the phages produced were recovered by precipitation using 8 g of PEG-8000 and 6 g 
of NaCl for 1 hour on ice. Next, the phages were centrifuged at 8000 rpm for 20 minutes at 4°C. The 
supernatant was discarded and the pellet dried by inverting on a paper towel, resuspended in 2 ml of PBS 
1x and transferred to a 2 ml eppendorf. To eliminate the remaining bacteria, a final centrifugation was 
performed at 13200 rpm for 5 minutes. Lastly, the phages supernatant was filtered through a 0.22 µm 
filter.  
 
 
2.5.2. Confirmation of library insert efficiency and diversity 
  
To confirm the library insert efficiency and diversity, PCR was performed. Individual colonies were picked 
into PCR tubes containing 20 µl of H2O and incubated for 5 minutes at 94°C in a thermocycler.  Then, PCR 
was performed using 5 µl of colony sample, 0.8 µl of primer RSC-F (20 pmol), 0.8 µl of primer RSC-B (20 
pmol), 5 µl PCR Buffer (5X), 1.5 µl of MgCl2 (50 mM), 0.5 µl of dNTPs (10 mM), 0.2 µl of Phusion High 
Fidelity DNA polymerase (Thermo Scientific)  and miliQ water to a final volume of 25 µl. The amplification 
conditions used are mentioned above. PCR products were evaluated on a 2% agarose gel by ethidium 
bromide staining under UV light with Chemidoc™ XRS+ (Bio-Rad). 
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2.6. Selection of specific sdAbs against the CD20 receptor by 
phage display 
 
For each VH and VL library, four selection rounds were performed and two types of cells were used for 
selection: positive cells - Raji; negative cells - HEK 293T.   
A total of 5 x 106 cells were used for each type. Cells were washed twice with PBS 1x and blocked with 
PBS/BSA 1%, at RT for 15 minutes, as well as the fresh phages for each library. Next, 300 µl of blocked 
phages were added to the blocked HEK 293T cells, and incubated for 15 minutes at 37°C. After incubation, 
the cells were centrifuged at 300 g for 5 minutes at RT, the supernatant recovered and added to the Raji 
cells. Raji cells were incubated with phages for 1.5 hours at 37°C, and the tubes inverted every 30 minutes 
to mix. After incubation, the tubes were centrifuged at 300 g for 5 minutes, and the cells pellet washed 
with PBS 1x, followed by several centrifugations. In the first panning, three wash steps were performed. 
In the second panning, six wash steps were performed, and in the third and fourth pannings, the cells were 
washed eight times. After the final wash, the cells were resuspended in 200 µl of pre-warmed trypsin and 
incubated at 37°C for 7 minutes. Next, the trypsin was immediately diluted with 1.2 ml of PBS 1x and the 
cells were centrifuged at 300 g for 5 minutes. The phages in the supernatant were named trypsin phages 
(or binder phages) and stored at 4°C. Then, the cells pellet was washed twice with PBS 1x and the 
supernatant discarded. To recover internalized phages, a cell lysis with 200 µl of PBS-Tween20 0.5% was 
performed, and the cells were incubated for 7 minutes at 37°C. Next, the cells were centrifuged at 300 g 
for 5 minutes and the supernatant containing internalized phages recovered and stored at 4°C. 
After a round of panning, a phage reamplification was performed. To reamplify, it was necessary to grow 
E.coli ER2738 bacteria from a fresh plate in 10 ml of SB medium containing 20 µl of tetracycline at 37°C at 
200 rpm until reaching an O.D. of approximately 0.6 - 0.7. Then, each phage (trypsin or internalized) was 
infected with 4 ml of bacteria and incubated for 15 minutes at 37°C. Next, 4 ml of pre-warmed SB medium 
with 1.6 µl of ampicillin and 8 µl of tetracycline was added to the culture. The culture was incubated for 1 
hour at 37°C, agitated at 200 rpm. Then, 2.4 µl of ampicillin was added to the culture and incubated in the 
same conditions for 1 hour. After incubation, 1 ml of VCSM13 helper phage was added to the culture and 
incubated for 15 minutes at 37°C. Then, the culture was transferred to a 250 ml Erlenmeyer containing 91 
mL of pre-warmed SB medium with 46 µl of ampicillin and 184 µl of tetracycline. The culture was incubated 
for 1.5 hours at 37°C, agitated at 200 rpm. After, 140 µl of kanamycin was added and the culture incubated 
overnight, agitated at 200 rpm at 37°C.  
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The following day, phage precipitation was performed as described previously, and then a new round of 
selection was performed (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 - Schematic representation of a round of selection (panning) for phage display. 
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2.7. Screening and characterization of sdAbs against the CD20 
receptor 
2.7.1. Cloning of selected sdAbs genes against the CD20 receptor into the 
pT7-PL (pT7-peptide leader) vector  
 
DNA into pComb3x was extracted from bacteria of the fourth panning of each phage display screening 
using a QIAprep® Spin Miniprep Kit (Qiagen), according to the manufacturer’s instructions, as described 
above, and then a digestion with restriction enzyme Sfi I was performed, according to the conditions also 
described above. After, the digested products were purified in order to separate the vector from the 
fragments with the desired size. Next, the purified DNA was inserted into pT7-PL vector using the T4 ligase 
enzyme, 50 ng of vector, 150 ng of VL or VH digested products, according to the conditions mentioned 
above.  
Then, transformation was performed, using 2 µl of ligation and 100 µl of E.coli BL21 cells. The conditions 
used were the same as the ones described previously. After incubation for 1 hour at 37°C, 200 rpm with 
SOC medium, 10 and 100 µl of each ligation were plated in LB + Amp plates. The next day, a confirmation 
of library insert efficiency was performed, as mentioned above. 
 
 
2.7.2. Expression and selection of specific antibodies  
 
The colonies obtained previously through transformation into E.coli BL21 cells were picked and 
incubated overnight at 30°C on 100 µl of SB medium containing Overnight Express™ Autoinduction System 
1 (Novagen®) and 100 µg/ml of Ampicilin. Next day, 40 µl of BugBuster (Roche) containing anti-protease 
cocktail-EDTA free inhibitors (Roche) were added and incubated for 30 minutes at 4°C. Next, the plates 
were centrifuged at 2000 rpm, for 10 minutes, and the supernatant was used to perform an ELISA assay. 
Three types of parameters were analyzed: binding of antibodies to the antigen, level of expression and 
unspecific binding. To evaluate the binding to the antigen (CD20), plates with the total Raji cell extract 
attached were used, then washed three times with PBS 1x and blocked with BSA 3% for 1 hour at 30°C. 
Then, the plates were washed again five times and the supernatant containing VLs or VHs was incubated 
for 1 hour at 30°C. The plates were washed again 5 times and anti-HA-HRP antibody (Roche) was added. 
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After 1 hour of incubation, the plates were washed 5 times, ABTS (Roche) substrate solution was added 
and the optical density at 405 nm was measured at different time points. To evaluate the level of 
expression, the same process was carried out except the coating of the plates with antigen. To evaluate 
the unspecific binding, in turn of the antigen, BSA 3% was added. Rabbit serum and anti-CD20 antibody 
were used as positive controls. BL21 extracts and SB medium were used as negative controls. 
The best clones were chosen and a new ELISA assay with extracts and Raji cells were performed to 
evaluate the binding of antibodies to the CD20 in a native conformation.  
 
 
2.7.3. Sequencing of anti-CD20 clones  
 
Sequencing was performed by GATC using the pComb3x ATG primer. To translate to amino acid 
sequences and, in order to evaluate their homology, the “Vector NTI” software was utilized. 
 
 
2.7.4. Confirmation of the specificity for the CD20 by Western Blot 
 
In order to verify if the selected clones were specific to the CD20 receptor, Western Blot was performed. 
Membranes blotted with the Raji, HEK 293T and Jurkat cells were incubated with the clones using anti-HA-
HRP (Roche) as secondary antibody.  
The clones for the Western Blot were purified using a Talon® spin column. The column was equilibrated 
with the equilibration/wash buffer, containing 50 mM of NaH2PO4, 300 mM of NaCl and 20 mM of 
Imidazole. Bound proteins were eluted from the column with 50 mM of NaH2PO4, 300 mM of NaCl and 
150 mM of Imidazole.  
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3. Results and discussion  
3.1. Rabbit immunizations  
 
The rabbit antibody repertoire has been used for decades in diagnostic applications in the form of 
polyclonal antibodies.  Now it also holds great promise as a source for generation of therapeutic mAbs. 
Moreover, over the past decade, rabbit derived sdAbs have been shown to have a great potential for 
therapeutic applications.31,32 Therefore, in this project we have explored rabbit derived sdAbs to develop 
new and potent antibodies against the CD20 receptor. In order achieve the proposal goal, one rabbit was 
immunized with the CD20 peptide and HEK 293T cells transfected with the CD20 vector. The rabbit was 
immunized for 84 days and euthanasia performed on day 89 according with the schedule shown on Table 
1. 
 
 
To evaluate serum specificity and titer, serum was collected according to the table 1 and analyzed by 
ELISA. The results corresponding to ELISA with pre and final bleed against the Raji cells are shown in Figure 
8. Raji cells are B cells that express the CD20 receptor. These results show that the final bleed serum 
recognized the Raji cells contrarily to pre-bleed that did not, which also occurs in the ELISA with the CD20 
peptide (Fig. 8). It also shows that immunizations resulted in a strong immune response as the serum titer 
was higher, as was expected for rabbit immunizations with cells.27 Moreover, it is also import to mention 
that no bind was observed for HEK 293T cells (data not shown). Therefore, the rabbit was euthanized and 
BM and SP extracted.  
Table 1 - Rabbit immunization schedule. 
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3.2. sdAbs immune library construction  
3.2.1. RNA extraction and cDNA synthesis 
 
Immunized sdAbs libraries were constructed using the RNA and cDNA obtained from the rabbit BM and 
SP. These sources were chosen because they have been shown to be a major repository of plasma cells 
that secretes antibodies used for construction of immune libraries.27 RNA and cDNA were extracted and 
synthetized as described in the material and methods section. In order to evaluate their concentration and 
purity, absorbance at 260 nm was measured, and integrity analyzed in agarose gel electrophoresis. RNA 
and cDNA yields and purity were as expected and according to data obtained for rabbit immunizations 
(Table 2 and Fig. 9).27 
Figure 9 - Samples of RNA extracted and cDNA synthetized from the BM and SP were eletrophoretically separated on a 1% 
agarose gel. (1 and 4 - Ladder 1kb; 2 - RNA BM; 3 - cDNA BM; 5 - RNA SP; 6 - cDNA SP) 
Table 2 - Quantification of RNA and cDNA from BM and SP of immunized rabbit. 
Figure 8 - Titration and binding activity of serum antibodies corresponding to pre and final bleed. Antisera from the immunized 
rabbit was analyzed for binding to Raji cells (A) and human CD20 peptide (B) by ELISA using HRP-conjugated goat anti-rabbit Fc 
polyclonal antibody as secondary antibody. Data were obtained by Abs measurement at 405 nm with reference a 492 nm. Values 
represent mean±standard deviation of triplicates (n=3) for each condition, and similar results were obtained in two independent 
experiments.  
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3.2.2. PCR amplification of single domains genes 
 
Immune sdAbs libraries were constructed using knowledge of the immunoglobulin variable regions 
sequence.27 Light (VL) and heavy (VH) chains were amplified separately according to the conditions 
described in the material and methods section. The VL regions were amplified from BM and SP cDNA using 
the VL sense and reverse primers generating fragments with 350 bp. The VH regions were amplified also 
from BM and SP cDNA by using the VH sense and reverse primers, originating fragments with 400 bp. PCR 
products had the expected size (Fig. 10).27 The amplification of the VH and VL families contributed to a 
higher diversity of immune libraries. Therefore, several PCRs were performed to achieve such diversity. All 
PCR products had a symmetric Sfi I sites on the 5’ and 3’ ends, which was required for cloning into the 
pComb3x vector.  
 
 
Figure 10 - PCR amplification of VL and VH families from BM and SP cDNA. Samples were run and separated on a 2% agarose gel. 
Amplification of VLs generated fragments with approximately 350 bp and VHs with about 400 bp. (1 and 6 - Ladder 1 kb; 2 - 
SDVH1+SDG; 3 - SDVH2+SDG; 4 - SDVH3+SDG; 5 - SDVH4+SDG; 7 - RSCVK1+SDVLj0; 8 - RSCVK1+SDVLj10; 9 - RSCVK1+SDVL42j0; 
10 - RSCVK2+SDVLj0; 11 - RSCVK2+SDVLj10; 12 - RSCVK2+SDVL42j0; 13 - RSCVK3+SDVLj0; 14 - RSCVK3+SDVLj10; 15 - 
RSCVK3+SDVL42j0; 16 - RSCλ+ SDVLλ). The arrows indicate the VL or VH PCR products.  
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3.2.3. Purification and cloning of PCR products into pComb3x vector 
 
After amplification, PCR products were purified in agarose gel as previously described. 45.2 µg and 25.7 
µg of DNA were recovered from the purification of VL BM and SP, respectively. Regarding the purification 
of VH BM and SP, 20.5 µg and 16.2 µg were recovered, respectively (Fig. 11).  
 
The purified DNA´s were then digested with the Sfi I restriction enzyme and purified again. 4.16 µg and 
4.5 µg of DNA were recovered from the purification of VL BM and VL SP, respectively. Regarding the 
purification of VH BM and SP, 5.3 µg of DNA were recovered from each one. The agarose gels regarding 
the purifications are presented below (Fig. 12). 
 
After digestion and purification, the DNA recovered was ligated into the pComb3x. Ligation was then 
inserted into E.coli ER2738 cells by electroporation, which is the most efficient method for transforming 
E.coli with plasmid DNA.  
Figure 11 - Purification of VL and VH domains after amplification in 2% low melting point agarose gel. For the VLs, the fragment 
corresponding to 350 bp was extracted from the gel. Regarding VH, the fragment corresponding to 400 bp was extracted from 
the gel. The arrows indicate the VL or VH products purified. Ladder 1kb as the DNA size control.  
Figure 12 - Purification of VL and VH domains after Sfi I restriction in 2% low melting point agarose gel. For the VLs, the fragment 
corresponding to 350 bp was extracted from the gel. Regarding VH, the fragment corresponding to 400 bp was extracted from 
the gel. The arrows indicate the VL and VH domains. Ladder 1kb as the DNA size control.  
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The number of independent transformants is very important, as it is used to describe the libraries’ 
complexity, allowing to determine the quality of the library. For the libraries derived from immune animals, 
the number of individual transformants must be in the range of 107 to 108.27  For the VL BM and SP libraries, 
the diversity was 8 x 107 and 2 x 107 transformants, respectively. The diversity obtained for the VH BM and 
SP libraries were 1.3 x 107 and 3.8 x 106 transformants. To confirm the libraries insert efficiency, PCR was 
performed as described in the material and methods section, using 10 clones of each library. An efficiency 
of 100% was obtained, meaning that all transformants had the insert cloned (Fig. 13). Because both 
libraries had a number of approximately 107 transformants, we can conclude that both libraries were 
efficiently constructed and are also representative, as they are highly diverse and complex.  
 
 
3.3. Selection of specific sdAbs by phage display 
 
After finishing the libraries construction, selection of specific sdAbs for the CD20 receptor were 
performed by a subtractive cell phage display as described in the material and methods section.  This cell 
phage display screening was based on the previously Carlos Barbas studies 27 were they reported a novel 
whole-cell selection protocol with negative and positive selection steps (subtractive phage display) 
designed to remove antibodies reacting with common antigens. The phage display conditions 
implemented in our project are summarized in Table 3. Briefly, the process was performed separately for 
the VL and VH libraries. The BM and SP libraries of each one were mixed together once they had a similar 
diversity. Four pannings were then performed with a subtractive selection with cells that do not express 
the CD20. For that, three types of cells (Raji, HEK 293T and Jurkat cells) were used that express different 
Figure 13 - Confirmation of the libraries insert efficiency for VL BM and SP libraries (A) and for VH BM and SP libraries (B). 
Samples were run and separated on a 1% agarose gel. The arrows indicate the VL and VH products. A) 1 and 22- Ladder 1 kb; 2 to 
11- VL BM clones; 12 to 21- VL SP clones; 23- C+ ; 24- C . B) 1 and 12- Ladder 1 kb; 2 to 11- VH BM clones; 13 to 22- VH SP clones; 
23- C+; 24- C-  
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receptors on their surface, contributing to a better selection of antibodies. The Raji cells were used in the 
positive selection since they are a stable B cell line that expresses the CD20 receptor. The HEK 293T and 
Jurkat cells do not express the CD20 receptor, so they were used in the subtractive selection for elimination 
of non-specific antibodies that bind to other receptors. The increase in the number of washes during the 
pannings also contributed to the removal of the antibodies that had a weak ligation to the cells, leading to 
the selection of the best antibodies. The elution’s performed were done to select for binders and 
internalized antibodies. Table 3 and Figure 14 show the results obtained for the VLs and VHs phage display. 
As shown, in all pannings there were a lower number of phages in the output titers compared to the input 
(~1011-12 to ~105-4 pfu). Moreover, it was also observed a decrease in the output phages from the 1st 
panning to the 2nd panning. Then, from the 2nd to the 3rd panning, the number of obtained phages 
maintained, and only increases in the 4th panning. This profile is expected for a phage display and 
demonstrated that the conditions implemented were leading to enrichment for specific antibodies-phages 
to our target. 
 
 
Table 3 - Results obtained from VL and VH domains selection by phage display and conditions used in each panning. 
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In order to confirm if the obtained sdAbs expressed on the phages surface were specific for the CD20 
receptor, western blot with amplified sdAbs expressed on the phages surface from the last panning was 
performed (Fig. 15). Membrane blotted with the protein extract of the Raji cells was incubated with the 
sdAbs-phages that were used as primary antibody, and as secondary the anti-M13-HRP (Roche). The 
results for the VL binders phages are presented below and show that the VL-phages recognized proteins 
in the cell extract in the range of 35 to 48 kDa.8 The CD20 protein has a molecular mass of approximately 
35 kDa, so it seems that the VL-phages are recognizing the CD20 receptor.  Regarding the VH phages, 
western blot had no success and no bands were obtained (data not shown).  
Figure 15 - Western blot analysis of the total cell extract from the Raji cells with the selected VL phage to evaluate the phage 
binding to the proteins of the cells. The phages were detected using the anti-M13 antibody. The arrow indicates the band 
corresponding to the CD20 receptor.  
Figure 14 – Graphs illustrating the results obtained from VL and VH domains selection by phage display.  
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Figure 17 - Confirmation of the percentage of inserts in VL (A) and VH (B) clones obtained after cloning into pT7-PL vector and 
transformation into E.coli BL21 cells. Each clone was eletrophoretically separated on a 1% agarose gel. The arrows indicate the 
VL or VH clones.  A) 1 and 22- Ladder 1 kb; 2 to 11- VL Binders; 12 to 21- VL Internalized; 23- C+; 24- C-. B) 1 and 12- Ladder 1 kb; 
2 to 11- VL Binders; 13 to 22- VL Internalized; 23- C+; 24- C-. 
3.4. Screening and characterization of sdAbs against the CD20 
receptor  
3.4.1. Cloning of the selected sdAbs genes against the CD20 receptor to the 
pT7-PL (pT7-peptide leader) vector  
 
After selection by phage display, it was necessary to select among the pool of antibodies against the 
CD20, those that had a better expression and binding to the target. To be able to select, it was necessary 
to clone the DNA corresponding to the VL and VH domains from the last panning into the pT7-PL vector. 
This vector has a peptide leader, allowing the expression of the sdAbs to be directed to the periplasmic 
space, making it possible to evaluate the expression level of sdAbs. DNA was digested with the restriction 
enzyme Sfi I, and purified on 2% agarose gel. The results are demonstrated in Figure 16. 
 
After purification, DNA was ligated into pT7-PL vector and inserted into E.coli BL21 cells by 
electroporation. In order to evaluate cloning efficiency, PCR was performed. An efficiency of 100% was 
obtained, meaning that all clones had a cloned insert (Fig. 17).  
 
 
 
 
 
 
  
 
Figure 16 - Purification of the VL and VH domains selected by phage display after Sfi I digestion. For the VL, the fragment 
correspondent to the 350 bp was recovered from the gel, and for the VH, the correspondent to the 400 bp. Each sample was 
separated on a 2% low melting point agarose gel. The arrows indicate the VL or VH domains selected. Ladder 1kb as the DNA size 
control.  
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3.4.2. Expression and selection of specific antibodies  
Once finalized the cloning of the VL and VH DNA (binders and internalized) into the pT7-PL vector, a high 
throughput screening was performed. A total of 528 clones, including VL and VH clones, were analyzed via 
ELISA assay to evaluate their expression and binding to the protein extract from Raji cells.  
The figure below demonstrates the results for the VL clones (Fig. 18).  
 
As shown in Figure 18, the clones that demonstrated having a stronger binding to the protein cell extract 
and expression were chosen, resulting in a binding percentage of 12.8 %. 
Regarding the VH clones, 14 were selected, resulting in a binder percentage of 5.30% (Fig. 19). 
For both selections, the expression levels were also considered and all selected clones demonstrated 
high expression levels. 
24 
Figure 18 - Relative binding activity of VL´s. A total of 264 VL clones were randomly selected for ELISA to evaluate their binding 
activity against Raji protein extracts and BSA. HRP-conjugated anti-HA mAb was used as secondary antibody. Results were 
measured by optical density at 405 nm. A total of 34 clones (12.8%) with 2-3 times higher binding for Raji extracts than BSA 
background signal were isolated. Rabbit serum and anti-CD20 antibody were used as positive controls. BL21 extracts and SB 
medium were used as negative controls. 
 
Figure 19 - Relative binding activity of VH´s. A total of 264 VH clones were randomly selected for ELISA to evaluate their binding 
activity against Raji protein extracts and BSA. HRP-conjugated anti-HA mAb was used as secondary antibody. Results were 
measured by optical density at 405 nm. A total of 14 clones (5.30 %) with 2-3 times higher binding than BSA background signal 
were isolated. BL21 extracts and SB medium were used as negative controls. 
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Each positive clone was tested again in ELISA assay with protein extract from Raji cells (data not shown). 
From this ELISA, 10 clones (9 VL binders and 1 VH binders) were selected and tested with Raji cells in order 
to evaluate the binding to the native CD20. The results of ELISA are presented in Figure 20. 
 
The figure above indicates that the 10 clones are binding to the Raji cells. As a result of cells expressing 
the CD20 receptor in native conformation, we can conclude that the clones are recognizing it not only in 
linear conformation in the protein extract, but also in its native conformation present in lymphoma cells.  
 
 
3.4.3. Sequencing of anti-CD20 clones 
  
In order to evaluate the clone’s profile, the 10 clones selected were sequenced and a homology analysis 
was performed by aligning the obtained amino acid sequences. The sequences analysis and respective 
homologies are present bellow.  
As shown, the resulting sequences demonstrate that 9 clones belong to the same family of VLs, K2/j0. 
The remaining clone belongs to the VH3 family. Moreover, we can observe that  the 9 VL clones are the 
same clone, since they have a homology of 100% (Fig. 21). Therefore, it seems that during the phage 
display there was a clone that was enrich during each panning.   
 
 
a) 
Figure 20 - Relative binding activity of best VL and VH´s lead candidates identified. A total of 10 clones (9 VL and 1 VH) were 
evaluated by cell ELISA for their binding activity against Raji cells. HRP-conjugated anti-HA mAb was used as secondary antibody. 
Rabbit serum was used as positive control and BL21 extracts and an irrelevant VL were used as negative control. Results were 
measured by optical density at 405 nm. Values represent mean±standard deviation of duplicates (n=2) for each condition, and 
similar results were obtained in two independent experiments.  
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3.5.4. Confirmation of specificity for the CD20 receptor 
 
By aligning the amino acid sequence obtained from sequencing, it was found that nine of the clones 
were equal, thus leaving only two clones (1 VL and 1 VH). The specificity of the two clones for the CD20 
receptor was evaluated by Western Blot, one of which (VL antibody format) was shown to be specific to 
the CD20 receptor. The result for the VL clone is shown below (Fig. 22). No binding was observed for the 
VH clone and further studies are in progress to evaluate his binding.   
 
The results of western blot show that the selected VL clone recognized proteins in the protein extract of 
the Raji cells, and did not recognize proteins in the cell extract of the HEK 293T or Jurkat cells. The 
recognized proteins’ molecular weight is approximately 35 kDa, which means that the chosen clone seems 
to be highly specific to the CD20 receptor.  
 
 
Figure 22 - Western blot analysis of the total cell extract from the Raji, HEK 293T and Jurkat cells with the selected clone. 
 
Figure 21 - Homology among amino acid sequences of selected clones. Homology tree obtained from the homology analysis 
of selected the clones.  
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4. Conclusion and future perspectives 
 
For decades, chemotherapy and radiotherapy had been the only treatments available for B cell 
lymphomas. However, with the discovery of Rituximab, new prospects in the field of immunotherapies 
became available. Throughout the years, the discovery of new antibodies for the CD20 receptor 
contributed to the development of new therapeutics and the quality of life of patients. Nevertheless, 
tumoral cells are always changing, making the search for better antibodies a never-ending process. 
To fight the necessity of searching for better antibodies, the development of a new, single domain 
antibody, specific for the CD20 receptor, was the goal of this project. Our approach began with several 
immunizations of one rabbit, resulting in a strong immune response. Complex and highly diverse immune 
libraries were then constructed. Subtractive and positive selection, performed by phage display, resulted 
in a specific pool of sdAbs-phages. Binding activity studies and sequencing of the resulting clones of this 
pool allowed us to select for two clones (1 VL and 1 VH). These results demonstrate that phage display in 
cells, using positive and negative cells, is an efficient method when the goal is to select against only one 
target. Finally, we demonstrated that the VL clone was specific for the CD20 receptor and the most 
promising sdAb candidate to proceed for further studies. The approaches and methodologies implement 
in this project were important and determinant, as they lead us to the goal of the project.  
The selected single domain antibody has many advantages compared to other antibodies because of its 
reduced size. Its reduced size allows the antibody to be used for several therapeutic applications related 
with B-cell malignancies. In the future, our single domain antibodies can be fused with an Fc region, leading 
to the recruitment of mechanisms in the immune system, such as apoptosis, complement activation, etc., 
to kill tumoral cells. The selected sdAbs could be also conjugated with a drug or toxin through a linker; and 
lastly, conjugated with a genetically modified T cell to form a chimeric antigen receptor (CAR-T cells). The 
applications of this sdAb could consist a future challenge. Furthermore, several in vitro studies (ex: epitope 
mapping, affinity measurements, cell activity, etc.) and in vivo studies related with the toxicity and 
efficiency of the sdAbs should be performed.    
In conclusion, the results of this project are promising and can contribute to the development of several 
immunotherapies, namely for the B-cell malignancies, once the selected sdAb proves itself to be a 
favorable candidate to be used as a therapeutic agent. Furthermore, using these approaches, more 
candidates can be selected by opening doors to the development of new molecules for cancer 
immunotherapies and other emerging diseases.  
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Supplementary data 
 
Supplementary figure 1- Molecular configuration of CD20 molecule. CD20 is a non-glycosylated phosphoprotein with four 
membranes spanning domains, the N - and C – terminal domains, which are intracytoplasmic and two additional extracellular 
loops.  Adapted from Cang et al, 2012.33 
Supplementary figure 2- Construct used for transfection of HEK 293T cells. This construct contains the sequence of the CD20 
and sequence coding for GFP inserted into pFUGW vector. 
Supplementary figure 3- Sequence of oligonucleotides used for amplification of genes which codifying for rabbit VL and VH 
single domain antibodies. 
